MOSCOW (Reuters) – The Russian Direct Investment Fund (RDIF) will sell 32 million doses of Sputnik V coronavirus vaccine to one of Mexico's leading pharmaceutical companies, a source close to the deal said Wednesday.
This is the second agreement for Russia to export COVID-19 vaccine.
The Sputnik V vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology, was registered in August. Post-registration tests, in which 40,000 volunteers are to take part, began on August 26.
Kazakhstan in August signed an agreement with RDIF to supply over 2 million doses of a potential vaccine after passing all tests. The country can increase its supply to 5 million doses.
The source said the deal with Mexico could be announced later Wednesday.
(Polina Ivanova. Translated by Vladimir Sadykov. Editor Marina Bobrova)